Next Article in Journal
Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties
Next Article in Special Issue
The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A
Previous Article in Journal
Microcystin-LR Does Not Alter Cell Survival and Intracellular Signaling in Human Bronchial Epithelial Cells
Previous Article in Special Issue
Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis
Open AccessReview

Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders—From Bench to Bedside

1
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan
2
Department of Urology, Buddhist Tzu Chi University, Hualien 970, Taiwan
3
Department of Nursing, Hualien Tzu Chi General Hospital, Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(3), 166; https://doi.org/10.3390/toxins12030166
Received: 1 February 2020 / Revised: 27 February 2020 / Accepted: 6 March 2020 / Published: 9 March 2020
Bladder oversensitivity arises from several different conditions involving the bladder, bladder outlet, systemic or central nervous system diseases. Increase of the bladder sensation results from activation of the sensory receptors in the urothelial cells or suburothelial tissues. Medical treatment targeting the overactive bladder (OAB) or interstitial cystitis (IC) might relieve oversensitive bladder symptoms (frequency, urgency and pain) in a portion of patients, but a certain percentage of patients still need active management. Botulinum toxin A (BoNT-A) has been demonstrated to have anti-inflammatory and antinociceptive effects in bladder sensory disorders and has been shown effective in the reduction of bladder oversensitivity and the increase of functional bladder capacity. For patients with OAB, urgency and urinary incontinence improved, while in patients with IC, bladder pain could be relieved in association with reduction of bladder oversensitivity after BoNT-A intravesical injection. Histological evidence has confirmed the therapeutic mechanism and clinical efficacy of intravesical BoNT-A injection on patients with OAB or IC. Bladder oversensitivity can also be relieved with the instillation of liposome encapsulated BoNT-A or low energy show waves (LESWs), which enable the BoNT-A molecule to penetrate into the urothelium and suburothelial space without affecting the detrusor contractility. Liposome encapsulated BoNT-A or combined LESWs and BoNT-A instillation might be future treatment alternatives for bladder oversensitivity in sensory bladder disorders. View Full-Text
Keywords: bladder; sensation; therapy; pathophysiology bladder; sensation; therapy; pathophysiology
MDPI and ACS Style

Jiang, Y.-H.; Yu, W.-R.; Kuo, H.-C. Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders—From Bench to Bedside. Toxins 2020, 12, 166.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop